Találati lista | Tudóstér

001-es BibID:	BIBFORM049222
Első szerző:	Rejtő László (belgyógyász, haematológus)
Cím:	A prolymphocytás leukaemia / Rejtő László
Dátum:	2000
Megjegyzések:	Polycythaemia vera and essential thrombocythaemia belong to the group of myeloproliferative diseases and are at present considered uncurable diseases. The aim of treatment is to decrease hemoglobin value and platelet count until they become normal and to avoid complications. For this purpose we employ (in polycythaemia vera) phlebotomy as well as radiophosohorus and alkylating drugs, which - due to their leukaemogenic effect - had been pushed into the background. Of these, hydroxyurea is the least leukaemogenic antineoplastic agent and therefore should be the first choice for treatment. Recombinant interferon (INF) with a complex therapeutic effect presents a novel possibility in the treatment of these diseases, since it does not have mutagenic and leukaemogenic effects. Its effect is dose dependent and it can also be employed during pregnancy. In polycythaemia vera 3x3 ME\m2 a week is suggested for inducation and 2-3x3 ME INF for maintenance treatment. Complete remission is expected in 60-70 per cent of the cases, partial remission in 10-20 per cent. In essential thrombocythaemia the suggested dosage is 3-5 ME 5-7 times a week and 3x3 ME a week for maintenance, gradually decreasing the dose until the smallest possibte but still effective dosage. Its efficacity is about 90 per cent (80-100 per cent).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban polycythaemia vera esszenciális thrombocythaemia interferon treatment purine analogues
Megjelenés:	Magyar Belorvosi Archívum. - 53 : 3 (2000), p. 171-173. -
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: